Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17327425 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPTSLC18A3RIPK1SIGMAR1 | |
| SCHEMBL18763714 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MAPTSLC18A3RIPK1SIGMAR1 | |
| SCHEMBL18763674 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPTSLC18A3RIPK1TRPA1 | |
| SCHEMBL18763672 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPTSLC18A3RIPK1TRPA1 | |
| SCHEMBL17327314 | 0.82 | ALDH1A1 (0.34) | ALDH1A1MAPTSLC18A3RIPK1TRPA1 | |
| SCHEMBL18763685 | 0.80 | ALDH1A1 (0.32) | ALDH1A1MAPTSLC18A3SIGMAR1TRPA1 | |
| SCHEMBL18790627 | 0.80 | ALDH1A1 (0.32) | ALDH1A1MAPTSLC18A3SIGMAR1TRPA1 | |
| SCHEMBL17327339 | 0.80 | ALDH1A1 (0.32) | ALDH1A1MAPTSLC18A3SIGMAR1TRPA1 | |
| SCHEMBL18763736 | 0.75 | HTT (0.34) | SIGMAR1HTT | |
| SCHEMBL18763739 | 0.75 | HTT (0.34) | SIGMAR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10987322-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2017-04-27 | — | — | US | disclosed |
| WO-2015188085-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112785-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | ALDH1A1 219/4885MAPT 2758/4885SLC18A3 1890/4885 |
| US-10987322-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | ALDH1A1 219/4885MAPT 2758/4885SLC18A3 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.